Cargando…

Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study

BACKGROUND: Carvedilol is a third-generation β-blocker indicated for congestive heart failure and high blood pressure. The aim of this study was to investigate the dose proportionality of the carvedilol sustained-release (SR) formulation in healthy male subjects. METHODS: An open-label, single dose-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yo Han, Choi, Hee Youn, Noh, Yook-Hwan, Lee, Shi Hyang, Lim, Hyeong-Seok, Kim, Chin, Bae, Kyun-Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468955/
https://www.ncbi.nlm.nih.gov/pubmed/26089641
http://dx.doi.org/10.2147/DDDT.S86168
_version_ 1782376574985699328
author Kim, Yo Han
Choi, Hee Youn
Noh, Yook-Hwan
Lee, Shi Hyang
Lim, Hyeong-Seok
Kim, Chin
Bae, Kyun-Seop
author_facet Kim, Yo Han
Choi, Hee Youn
Noh, Yook-Hwan
Lee, Shi Hyang
Lim, Hyeong-Seok
Kim, Chin
Bae, Kyun-Seop
author_sort Kim, Yo Han
collection PubMed
description BACKGROUND: Carvedilol is a third-generation β-blocker indicated for congestive heart failure and high blood pressure. The aim of this study was to investigate the dose proportionality of the carvedilol sustained-release (SR) formulation in healthy male subjects. METHODS: An open-label, single dose-ascending, 10-sequence, 3-period balanced incomplete block study was performed using healthy male subjects. In varying sequences, each subject received three of five carvedilol SR formulations (8, 16, 32, 64, or 128 mg once). The treatment periods were separated by a washout period of 7 days. Serial blood samples were collected up to 48 h after dosing. The plasma concentrations of carvedilol were determined by using validated liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters including the area under the plasma concentration–time curve (AUC) from time 0 to the last measurable time (AUC(last)), AUC extrapolated to infinity (AUC(inf)), and the measured peak plasma concentration (C(max)) were obtained by noncompartmental analysis. Dose proportionality was evaluated if the ln–ln plots of AUC(last), AUC(inf), and C(max) versus dose were linear and the 90% confidence intervals (CIs) of the slopes were within 0.9195 and 1.0805. Tolerability was assessed by vital signs, electrocardiogram, clinical laboratory tests, and monitoring of adverse events (AEs) throughout the study. RESULTS: A total of 31 subjects were enrolled, and 30 completed the study. The assessment of dose proportionality meets the statistical criteria; the point estimates of slope were 1.0104 (90% CI: 0.9849–1.0359) for AUC(last), 1.0003 (90% CI: 0.9748–1.0258) for AUC(inf), and 0.9901 (90% CI: 0.9524–1.0277) for C(max), respectively. All AEs were mild, and none of the subjects dropped out due to AEs. CONCLUSION: In this study, exposure to carvedilol was proportional over the therapeutic dose range of 8–128 mg. The carvedilol SR formulation was well tolerated.
format Online
Article
Text
id pubmed-4468955
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44689552015-06-18 Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study Kim, Yo Han Choi, Hee Youn Noh, Yook-Hwan Lee, Shi Hyang Lim, Hyeong-Seok Kim, Chin Bae, Kyun-Seop Drug Des Devel Ther Original Research BACKGROUND: Carvedilol is a third-generation β-blocker indicated for congestive heart failure and high blood pressure. The aim of this study was to investigate the dose proportionality of the carvedilol sustained-release (SR) formulation in healthy male subjects. METHODS: An open-label, single dose-ascending, 10-sequence, 3-period balanced incomplete block study was performed using healthy male subjects. In varying sequences, each subject received three of five carvedilol SR formulations (8, 16, 32, 64, or 128 mg once). The treatment periods were separated by a washout period of 7 days. Serial blood samples were collected up to 48 h after dosing. The plasma concentrations of carvedilol were determined by using validated liquid chromatography–tandem mass spectrometry. Pharmacokinetic parameters including the area under the plasma concentration–time curve (AUC) from time 0 to the last measurable time (AUC(last)), AUC extrapolated to infinity (AUC(inf)), and the measured peak plasma concentration (C(max)) were obtained by noncompartmental analysis. Dose proportionality was evaluated if the ln–ln plots of AUC(last), AUC(inf), and C(max) versus dose were linear and the 90% confidence intervals (CIs) of the slopes were within 0.9195 and 1.0805. Tolerability was assessed by vital signs, electrocardiogram, clinical laboratory tests, and monitoring of adverse events (AEs) throughout the study. RESULTS: A total of 31 subjects were enrolled, and 30 completed the study. The assessment of dose proportionality meets the statistical criteria; the point estimates of slope were 1.0104 (90% CI: 0.9849–1.0359) for AUC(last), 1.0003 (90% CI: 0.9748–1.0258) for AUC(inf), and 0.9901 (90% CI: 0.9524–1.0277) for C(max), respectively. All AEs were mild, and none of the subjects dropped out due to AEs. CONCLUSION: In this study, exposure to carvedilol was proportional over the therapeutic dose range of 8–128 mg. The carvedilol SR formulation was well tolerated. Dove Medical Press 2015-06-08 /pmc/articles/PMC4468955/ /pubmed/26089641 http://dx.doi.org/10.2147/DDDT.S86168 Text en © 2015 Kim et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kim, Yo Han
Choi, Hee Youn
Noh, Yook-Hwan
Lee, Shi Hyang
Lim, Hyeong-Seok
Kim, Chin
Bae, Kyun-Seop
Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
title Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
title_full Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
title_fullStr Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
title_full_unstemmed Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
title_short Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
title_sort dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468955/
https://www.ncbi.nlm.nih.gov/pubmed/26089641
http://dx.doi.org/10.2147/DDDT.S86168
work_keys_str_mv AT kimyohan doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy
AT choiheeyoun doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy
AT nohyookhwan doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy
AT leeshihyang doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy
AT limhyeongseok doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy
AT kimchin doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy
AT baekyunseop doseproportionalityandpharmacokineticsofcarvedilolsustainedreleaseformulationasingledoseascending10sequenceincompleteblockstudy